Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma

Bone Marrow Transplantation volume 33, pages 635–638 (2004)Cite this article

Summary:

Primary systemic anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) has a poor prognosis. This study sought to determine if high-dose therapy and ASCT results in long-term disease-free survival (DFS) in patients with recurrent, chemotherapy-sensitive ALK-negative ALCL. All patients with non-Hodgkin's lymphoma (NHL) who underwent ASCT at Wake Forest University and Upstate Medical University from 1 January 1990 to 12 December 2002 were reviewed to determine if they had T-, B- or null-cell NHL that was CD30+/CD15−/ALK negative. In all, 16 patients were thus identified as having ALK-negative ALCL. All 16 patients underwent ASCT at the time of first relapse and form the basis of this report. Median age of the 16 patients was 51 years. There were 11 males and five females. International prognostic index scores in 12 patients at the time of relapse were: low 3, LI 6 and HI 3. Of 15 patients, 13 relapsed after ASCT; one patient was lost to follow-up. Median progression-free survival for the 15 patients was 12 weeks (3–212+ weeks). Of 15 patients, 10 have died; nine of recurrent disease. Median overall survival for the 15 evaluable patients was 72 weeks. In our experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALK-negative ALCL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Stein H, Foss HD, Durkop H et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96: 3681–3695.

    CAS  PubMed  Google Scholar 

  2. Falini B . Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol 2001; 114: 741–760.

    CAS  PubMed  Google Scholar 

  3. Pulford K, Lamant L, Morris SW et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394–1404.

    CAS  PubMed  Google Scholar 

  4. Benharroch D, Meguerian-Bedoyan Z, Lamant L et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076–2084.

    CAS  PubMed  Google Scholar 

  5. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999; 93: 2697–2706.

    CAS  PubMed  Google Scholar 

  6. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913–3921.

    CAS  PubMed  Google Scholar 

  7. Fanin R, Ruiz de Elvira MC, Sperotto A et al. Autologous stem cell transplantation for T and null cell CD30+ anaplastic large cell lymphoma: analysis of 64 adult and pediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 23: 437–442.

    CAS  PubMed  Google Scholar 

  8. Blystad AK, Enblad G, Kvaloy S et al. High dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.

    CAS  PubMed  Google Scholar 

  9. Rodriguez J, Munsell M, Yazji S et al. Impact of high dose chemotherapy on peripheral T cell lymphomas. J Clin Oncol 2001; 19: 3766–3770.

    CAS  PubMed  Google Scholar 

  10. Delsol G, Ralkiaer E, Stein H et al. Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissue. IARC Press: Lyon, France, 2001, pp 230–235.

    Google Scholar 

  11. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

    Google Scholar 

  12. Ansell SM, Habermann TM, Witzig TE et al. Predictive capacity of international prognostic factor index in patients with peripheral T cell lymphoma. J Clin Oncol 1997; 15: 2296–2301.

    CAS  PubMed  Google Scholar 

  13. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high dose therapy in poor risk aggressive non-Hodgkin's lymphomas: final analysis of the prospective LNH 87-2 protocol – A Group d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 16: 3025–3030.

    Google Scholar 

  14. Deconinck E, Lamy T, Foussard C et al. Autologous stem cell transplantation for anaplastic large cell lymphomas: results of a prospective trial. Br J Haematol 2000; 109: 736–742.

    CAS  PubMed  Google Scholar 

  15. Mounier N, Simon D, Haioun C et al. Impact of high dose chemotherapy on peripheral T cell lymphoma. J Clin Oncol 2002; 20: 1426–1427, (letter).

    PubMed  Google Scholar 

  16. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 76–82.

    CAS  PubMed  Google Scholar 

  17. Rassidakis GZ, Sarris AH, Herling M et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol 2001; 159: 527–535.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. ten Berge RL, Meijer CJLM, Dukers DF et al. Expression levels of apoptosis related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540–4546.

    CAS  PubMed  Google Scholar 

  19. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large cell B cell lymphoma. N Engl J Med 2002; 346: 235–242.

    CAS  PubMed  Google Scholar 

  20. Delsol G, Saati TA, Gatter KC et al. Coexpression of epithelial membrane antigen (EMA), Ki-1 and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988; 130: 59–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Janik JE, Morris JC, Pittaluga S et al. Serum soluble IL-2 receptor levels are elevated in patients with anaplastic large cell lymphoma (ALCL). Blood 2002; 100: 2505a (abstract).

    Google Scholar 

Download references

Author information

Author notes

  1. K W Zamkoff

    Present address: State University of New York-Stony Brook, Health Science Center, StonyBrook, NY, 11794-8174, USA

Authors and Affiliations

  1. Division of Hematology and Oncology, Wake Forest University-Baptist Medical Center, Winston-Salem, NC, USA

    K W Zamkoff & M D Matulis

  2. Division of Hematology/Oncology, Upstate Medical University, Syracuse, NY, USA

    A C Mehta & T C Gentile

  3. Department of Pathology, Wake Forest University-Baptist Medical Center, Winston-Salem, NC, USA

    M W Beaty

  4. Department of Pathology, Upstate Medical University, Syracuse, NY, USA

    R E Hutchison

Authors
  1. K W Zamkoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M D Matulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A C Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M W Beaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R E Hutchison
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T C Gentile
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K W Zamkoff.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zamkoff, K., Matulis, M., Mehta, A. et al. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant 33, 635–638 (2004). https://doi.org/10.1038/sj.bmt.1704392

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704392

Keywords

This article is cited by

Search

Advanced search

Quick links